TY - JOUR
T1 - Labedipinedilol-A
T2 - A vanilloid-based α/β-adrenoceptor blocker with calcium entry blocking and long-acting antihypertensive properties
AU - Liang, Jhy Chong
AU - Yeh, Jwu Lai
AU - Chiang, Lien Chai
AU - Yang, Yu Chiao
AU - Sheu, Sheng Hsiung
AU - Lai, Wen Ter
AU - Chen, Ing Jun
PY - 2000
Y1 - 2000
N2 - The combination of β-adrenoceptor blockade and vasodilator action have proved highly useful in antihypertensive therapy. Studies of the mechanisms of action of labedipinedilol-A that combine these effects within a single molecule are described in this report. Intravenous labedipinedilol-A (0.1-1.0 mg/kg) produced dose-dependent hypotensive and bradycardia responses for above 1.0 h, significantly different from nifedipine (0.5 mg/kg, i.v.)- induced hypotensive and reflex tachycardia activities in pentobarbital- anesthetized Wistar rats. Pretreatment with labedipinedilol-A also inhibited phenylephrine (20 μg/kg, i.v.)-induced hypertensive and (-)isoprenaline (0.5 μg/kg, i.v.)-induced tachycardia effects. Oral administration of labedipinedilol-A (5-50 mg/kg) in spontaneously hypertensive rats (SHR) reduced the blood pressure and heart rate for 24 h but did not increase heart rate. Labedipinedilol-A (10-7 -10-5 M) competitively antagonized (- )isoprenaline (10-10-10-4M)-induced positive chronotropic and inotropic effects of the isolated rat atria and tracheal relaxation responses of the isolated guinea pig tissues. Labedipinedilol-A also prevented the rate- increasing effects of increased extracellular Ca2+ (3.0-9.0 mM) in a concentration-dependent manner. In the isolated rat aorta, labedipinedilol-A competitively antagonized CaCl2 and norepinephrine-induced contractions with pKCa-1 and pA2 values of 8.46 ± 0.05 and 8.28 ± 0.03 and had a potent effect of inhibiting high K+ -induced vasocontraction. Furthermore, labedipinedilol-A, in an equal antagonist activity, inhibited norepinephrine- induced phasic and tonic contraction. In the cultured blood vessel smooth muscle cell (A7r5 cell line), KCl, norepinephrine, and Bay K 8644-induced intracellular calcium changes were decreased after application of labedipinedilol-A (10-9-10-6 M). The binding characteristics of labedipinedilol-A were evaluated in [3H]CGP-12177 binding to ventricle and lung and [3H]nitrendipine and [3H]prazosin binding to brain membranes in rats. The -logIC50 values of labedipinedilol-A for β1-, β2-, and α1- adrenoceptor and calcium channel, were 8.17 x 10-7 M, 8.20 x 10-7 M, 2.20 x 10-8 M, and 2.46 x 10-8 M, respectively. Labedipinedilol-A-induced sustained depressor effect was mainly attributed to its calcium entry and α- adrenoceptor blocking activities in the blood vessel. Sustained bradycardia effect resulted from β-adrenoceptor and calcium entry blocking, which deleted the sympathetic activation-associated reflex tachycardia in the heart. (C) 2000 Wiley-Liss, Inc.
AB - The combination of β-adrenoceptor blockade and vasodilator action have proved highly useful in antihypertensive therapy. Studies of the mechanisms of action of labedipinedilol-A that combine these effects within a single molecule are described in this report. Intravenous labedipinedilol-A (0.1-1.0 mg/kg) produced dose-dependent hypotensive and bradycardia responses for above 1.0 h, significantly different from nifedipine (0.5 mg/kg, i.v.)- induced hypotensive and reflex tachycardia activities in pentobarbital- anesthetized Wistar rats. Pretreatment with labedipinedilol-A also inhibited phenylephrine (20 μg/kg, i.v.)-induced hypertensive and (-)isoprenaline (0.5 μg/kg, i.v.)-induced tachycardia effects. Oral administration of labedipinedilol-A (5-50 mg/kg) in spontaneously hypertensive rats (SHR) reduced the blood pressure and heart rate for 24 h but did not increase heart rate. Labedipinedilol-A (10-7 -10-5 M) competitively antagonized (- )isoprenaline (10-10-10-4M)-induced positive chronotropic and inotropic effects of the isolated rat atria and tracheal relaxation responses of the isolated guinea pig tissues. Labedipinedilol-A also prevented the rate- increasing effects of increased extracellular Ca2+ (3.0-9.0 mM) in a concentration-dependent manner. In the isolated rat aorta, labedipinedilol-A competitively antagonized CaCl2 and norepinephrine-induced contractions with pKCa-1 and pA2 values of 8.46 ± 0.05 and 8.28 ± 0.03 and had a potent effect of inhibiting high K+ -induced vasocontraction. Furthermore, labedipinedilol-A, in an equal antagonist activity, inhibited norepinephrine- induced phasic and tonic contraction. In the cultured blood vessel smooth muscle cell (A7r5 cell line), KCl, norepinephrine, and Bay K 8644-induced intracellular calcium changes were decreased after application of labedipinedilol-A (10-9-10-6 M). The binding characteristics of labedipinedilol-A were evaluated in [3H]CGP-12177 binding to ventricle and lung and [3H]nitrendipine and [3H]prazosin binding to brain membranes in rats. The -logIC50 values of labedipinedilol-A for β1-, β2-, and α1- adrenoceptor and calcium channel, were 8.17 x 10-7 M, 8.20 x 10-7 M, 2.20 x 10-8 M, and 2.46 x 10-8 M, respectively. Labedipinedilol-A-induced sustained depressor effect was mainly attributed to its calcium entry and α- adrenoceptor blocking activities in the blood vessel. Sustained bradycardia effect resulted from β-adrenoceptor and calcium entry blocking, which deleted the sympathetic activation-associated reflex tachycardia in the heart. (C) 2000 Wiley-Liss, Inc.
KW - 1,4-dihydropyridines
KW - Calcium channel blockade
KW - Vanilloid-based
KW - α/β-adrenoceptor blockade
UR - http://www.scopus.com/inward/record.url?scp=0033911860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033911860&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1098-2299(200002)49:2<94::AID-DDR3>3.0.CO;2-V
DO - 10.1002/(SICI)1098-2299(200002)49:2<94::AID-DDR3>3.0.CO;2-V
M3 - Article
AN - SCOPUS:0033911860
SN - 0272-4391
VL - 49
SP - 94
EP - 108
JO - Drug Development Research
JF - Drug Development Research
IS - 2
ER -